Table 3.
Attributes and Challenges Relevant to Patient INCS Adherence, Overall and by Country
| All (N=1436) | Brazil (n=202) | Mexico (n=200) | SA (n=217) | UAE (n=207) | Japan (n=200) | Korea (n=200) | Spain (n=110) | UK (n=100) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Importance of attribute in helping patient adherence to INCS | Quick symptom relief,a n (%) | |||||||||
| Very important | 1007 (71.6) | 171 (87.2) | 157 (78.5) | 156 (71.9) | 164 (79.2) | 67 (36.0) | 154 (77.0) | 69 (63.9) | 69 (75.0) | |
| Somewhat important | 323 (23.0) | 22 (11.2) | 40 (20) | 53 (24.4) | 41 (19.8) | 75 (40.3) | 37 (18.5) | 34 (31.5) | 21 (22.8) | |
| Slightly important | 63 (4.5) | 2 (1.0) | 3 (1.5) | 6 (2.8) | 2 (1.0) | 36 (19.4) | 8 (4.0) | 5 (4.6) | 1 (1.1) | |
| Not at all important | 13 (0.9) | 1 (0.5) | 0 | 2 (0.9) | 0 | 8 (4.3) | 1 (0.5) | 0 | 1 (1.1) | |
| Easy to take or administer,a n (%) | ||||||||||
| Very important | 652 (50.2) | 96 (49.0) | 153 (76.5) | 128 (59.0) | 109 (52.7) | 54 (29.3) | 115 (57.5) | 54 (50.0) | 47 (51.6) | |
| Somewhat important | 469 (36.1) | 86 (43.9) | 40 (20.0) | 67 (30.9) | 69 (33.3) | 79 (42.9) | 70 (35.0) | 28 (25.9) | 30 (33.0) | |
| Slightly important | 146 (11.2) | 11 (5.6) | 7 (3.5) | 20 (9.2) | 19 (9.2) | 46 (25.0) | 12 (6.0) | 22 (20.4) | 9 (9.9) | |
| Not at all important | 32 (2.5) | 3 (1.5) | 0 | 2 (0.9) | 10 (4.8) | 5 (2.7) | 3 (1.5) | 4 (3.7) | 5 (5.5) | |
| Long nozzle,b,c n (%) | ||||||||||
| Very important | 63 (40.6) | 6 (60.0) | 9 (52.9) | 24 (35.3) | 18 (66.7) | 1 (16.7) | 0 | 3 (25.0) | 2 (20.0) | |
| Somewhat important | 44 (28.4) | 0 | 2 (11.8) | 23 (33.8) | 6 (22.2) | 3 (50.0) | 4 (80.0) | 3 (25.0) | 3 (30.0) | |
| Slightly important | 22 (14.2) | 0 | 4 (23.5) | 10 (14.7) | 2 (7.4) | 1 (16.7) | 1 (20.0) | 2 (16.7) | 2 (20.0) | |
| Not at all important | 23 (14.8) | 4 (40.0) | 2 (11.8) | 9 (13.2) | 1 (3.7) | 0 | 0 | 4 (33.3) | 3 (30.0) | |
| Not familiar with this feature | 3 (1.9) | 0 | 0 | 2 (2.9) | 0 | 1 (16.7) | 0 | 0 | 0 | |
| Short nozzle in helping take INCS,b,c n (%) | ||||||||||
| Very important | 37 (24.3) | 2 (20.0) | 3 (17.6) | 20 (29.9) | 9 (33.3) | 0 | 1 (20.0) | 1 (8.3) | 1 (11.1) | |
| Somewhat important | 52 (34.2) | 0 | 3 (17.6) | 27 (40.3) | 14 (51.9) | 1 (20.0) | 1 (20.0) | 4 (33.3) | 2 (22.2) | |
| Slightly important | 29 (19.1) | 4 (40.0) | 7 (41.2) | 9 (13.4) | 2 (7.4) | 2 (40.0) | 2 (40.0) | 1 (8.3) | 2 (22.2) | |
| Not at all important | 31 (20.4) | 4 (40.0) | 4 (23.5) | 9 (13.4) | 2 (7.4) | 1 (20.0) | 1 (20.0) | 6 (50.0) | 4 (44.4) | |
| Not familiar with this feature | 3 (2.0) | 0 | 0 | 2 (3.0) | 0 | 1 (20.0) | 0 | 0 | 0 | |
| Very fine spray/mist,c n (%) | ||||||||||
| Very important | 61 (39.6) | 8 (80.0) | 11 (64.7) | 20 (29.9) | 13 (48.1) | 0 | 2 (40.0) | 2 (16.7) | 5 (45.5) | |
| Somewhat important | 47 (30.5) | 1 (10.0) | 3 (17.6) | 24 (35.8) | 8 (29.6) | 1 (20.0) | 3 (60.0) | 2 (16.7) | 5 (45.5) | |
| Slightly important | 32 (20.8) | 0 | 3 (17.6) | 15 (22.4) | 5 (18.5) | 3 (60.0) | 0 | 5 (41.7) | 1 (9.1) | |
| Not at all important | 13 (8.4) | 1 (10.0) | 0 | 7 (10.4) | 1 (3.7) | 1 (20.0) | 0 | 3 (25.0) | 0 | |
| Not familiar with this feature | 1 (0.6) | 0 | 0 | 1 (1.5) | 0 | 0 | 0 | 0 | 0 | |
| Presence of a dose counter,b,c n (%) | ||||||||||
| Very important | 58 (37.4) | 8 (80.0) | 12 (70.6) | 22 (32.4) | 7 (26.9) | 2 (40.0) | 0 | 4 (30.8) | 3 (27.3) | |
| Somewhat important | 57 (36.8) | 2 (20.0) | 0 | 26 (38.2) | 16 (61.5) | 1 (20.0) | 3 (60.0) | 6 (46.2) | 3 (27.3) | |
| Slightly important | 20 (12.9) | 0 | 4 (23.5) | 8 (11.8) | 2 (7.7) | 0 | 2 (40.0) | 1 (7.7) | 3 (27.3) | |
| Not at all important | 14 (9.0) | 0 | 1 (5.9) | 9 (13.2) | 0 | 0 | 0 | 2 (15.4) | 2 (18.2) | |
| Not familiar with this feature | 6 (3.9) | 0 | 0 | 3 (4.4) | 1 (3.8) | 2 (40.0) | 0 | 0 | 0 | |
| Long-lasting symptom relief,a n (%) | ||||||||||
| Very important | 972 (69.1) | 167 (85.2) | 156 (78.0) | 139 (64.1) | 136 (65.7) | 69 (37.1) | 156 (78.0) | 81 (75.0) | 68 (73.9) | |
| Somewhat important | 353 (25.1) | 28 (14.3) | 42 (21.0) | 65 (30.0) | 63 (30.4) | 71 (38.2) | 38 (19.0) | 25 (23.1) | 21 (22.8) | |
| Slightly important | 71 (5.0) | 0 | 2 (1.0) | 11 (5.1) | 7 (3.4) | 41 (22.0) | 5 (2.5) | 2 (1.9) | 3 (3.3) | |
| Not at all important | 10 (0.7) | 1 (0.5) | 0 | 2 (0.9) | 1 (0.5) | 5 (2.7) | 1 (0.5) | 0 | 0 | |
| Bothersome attributes that may present treatment challenges | Bad taste,a n (%) | |||||||||
| Extremely bothersome | 390 (28.2) | 98 (50.3) | 29 (14.5) | 116 (53.5) | 110 (53.1) | 15 (8.5) | 4 (2.0) | 12 (12.0) | 6 (6.7) | |
| Moderately bothersome | 356 (25.7) | 41 (21.0) | 74 (37.0) | 76 (35.0) | 53 (25.6) | 56 (31.6) | 23 (11.6) | 20 (20.0) | 13 (14.4) | |
| Slightly bothersome | 340 (24.6) | 23 (11.8) | 61 (30.5) | 19 (8.8) | 35 (16.9) | 60 (33.9) | 73 (36.9) | 39 (39.0) | 30 (33.3) | |
| Not bothersome | 298 (21.5) | 33 (16.9) | 36 (18.0) | 6 (2.8) | 9 (4.3) | 46 (26.0) | 98 (49.5) | 29 (29.0) | 41 (45.6) | |
| How bothersome is dripping down throat in taking INCS,a n (%) | ||||||||||
| Extremely bothersome | 337 (24.6) | 85 (43.8) | 35 (17.5) | 94 (43.3) | 81 (39.1) | 13 (7.4) | 2 (1.0) | 19 (19.6) | 8 (8.9) | |
| Moderately bothersome | 410 (29.9) | 52 (26.8) | 84 (42.0) | 74 (34.1) | 81 (39.1) | 61 (34.9) | 23 (11.8) | 19 (19.6) | 16 (17.8) | |
| Slightly bothersome | 336 (24.5) | 31 (16.0) | 50 (25.0) | 45 (20.7) | 32 (15.5) | 56 (32.0) | 54 (27.7) | 34 (35.1) | 34 (37.8) | |
| Not at all bothersome | 289 (21.1) | 23 (13.4) | 31 (15.5) | 4 (1.8) | 13 (6.3) | 45 (25.7) | 116 (59.5) | 25 (25.8) | 32 (35.6) | |
| How bothersome is drowsiness,a n (%) | ||||||||||
| Extremely bothersome | 239 (17.7) | 41 (23.2) | 21 (10.5) | 75 (34.6) | 55 (26.6) | 21 (12.5) | 0 | 15 (15.3) | 11 (12.8) | |
| Moderately bothersome | 348 (25.8) | 34 (19.2) | 60 (30.0) | 95 (43.8) | 85 (41.1) | 40 (23.8) | 8 (4.1) | 17 (17.3) | 9 (10.5) | |
| Slightly bothersome | 300 (22.2) | 56 (31.6) | 46 (23.0) | 32 (14.7) | 34 (16.4) | 52 (31.0) | 44 (22.4) | 23 (23.5) | 13 (15.1) | |
| Not bothersome | 462 (34.2) | 46 (26.0) | 73 (36.5) | 15 (6.9) | 33 (15.9) | 55 (32.7) | 144 (73.5) | 43 (43.9) | 53 (61.6) | |
Notes: All values shown are percentages/means for evaluable participant responses (not all patients surveyed responded to every question). ap<0.001 (Chi-squared test). bp<0.01 (Chi-squared test). cOf those who changed INCS device in the past 12 months.
Abbreviations: INCS, intranasal corticosteroid; SA, Saudi Arabia; UAE, United Arab Emirates; UK, United Kingdom.